Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 310-321

  Zhang, Bin ^a   Suer, Silke ^c   Livak, Ferenc ^a   Adediran, Samusi ^a   Vemula, Arvind ^a   Khan, Mohammad Afnan ^a   Ning, Yi ^b   Hussain, Arif ^a,d  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; GLYCOPROTEIN P; KML 001; PACLITAXEL; SODIUM META ARSENITE; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROTUBULE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIDE POPULATION CELL; TELOMERE; TELOMERE HOMEOSTASIS; WILD TYPE;

CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICROTUBULES; PACLITAXEL; PROSTATIC NEOPLASMS; TAXOIDS; TELOMERE; TREATMENT OUTCOME;

EID: 84863925565     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.076752     Document Type: Article

References (51)

1. Ajana I, Astier A, and Gibaud S (2009) Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. J Pharm Pharmacol 61:1295-1301.
2. Baerlocher GM, Vulto I, de Jong G, and Lansdorp PM (2006) Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 1:2365-2376.
3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, and Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245.
4. Burger AM (2002) Standard TRAP assay, in Telomeres and Telomerase: Methods in Molecular Biology (Double JA and Thompson MJ eds) pp 109-124, Humana Press, Totowa, NJ.
5. Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ, Double JA, and Neidle S (2005) The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 65:1489-1496.
6. Burger AM and Harnden P (1998) Telomerase in germ cell tumours: inhibition of telomerase activity after cisplatin-based therapy, in Germ Cell Tumours IV (Jones I, Appelyard I, Harnden P, and Joffe JK eds) pp 73-80, John Libbey & Co., London.
7. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, and Chen GQ (2003) Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 17:1333-1337.
8. Chou TC (2008) Preclinical versus clinical drug combination studies. Leuk Lymphoma 49:2059-2080.
9. Chou TC and Hayball MP (1977) CalcuSyn for Windows: Multiple-Drug Dose-Effect Analyzer and Manual, Biosoft, Cambridge, UK.
10. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
11. Collins AT, Berry PA, Hyde C, Stower MJ, and Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951.
12. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, and Jackson SP (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426:194-198.
13. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, et al. (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71:6019-6029.
14. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005.
15. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154.
16. Deschatrette J, Ng KH, Gouthière L, Maigné J, Guerroui S, and Wolfrom C (2004) Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells. Anticancer Drugs 15:671-678.
17. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al. (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822.
18. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, et al. (2008) Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111:566-573.
19. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, and Huang H (2009) Inhibition of the androgen receptor as a novel mechanism of Taxol chemotherapy in prostate cancer. Cancer Res 69:8386-8394.
20. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, and Jalili M (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29:2753-2757.
21. Goodell MA, Brose K, Paradis G, Conner AS, and Mulligan RC (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183:1797-1806.
22. Greenberger LM and Sampath D (2006) Resistance to taxanes, in Cancer Drug Resistance (Teicher BA ed) pp 329-358, Humana Press, Totowa, NJ.
23. Grossi A and Biscardi M (2004) Reversal of MDR by verapamil analogues. Hematology 9:47-56.
24. Han YH, Moon HJ, You BR, Kim SZ, Kim SH, and Park WH (2010) Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types. Int J Mol Med 25:121-128.
25. Ishibashi T and Lippard SJ (1998) Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 95:4219-4223.
26. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. (2010) Sipuleucel-Timmunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422.
27. Li YM and Broome JD (1999) Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59:776-780.
28. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, and Lin FF (1998) Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 273:5939-5947.
29. Ling YH, Jiang JD, Holland JF, and Perez-Soler R (2002) Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 62:529-538.
30. -ΔΔCT method. Methods 25:402-408.
31. Mei N, Kunugita N, Hirano T, and Kasai H (2002) Acute arsenite-induced 8-hydroxyguanine is associated with inhibition of repair activity in cultured human cells. Biochem Biophys Res Commun 297:924-930.
32. Miller WH Jr, Schipper HM, Lee JS, Singer J, and Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903.
33. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, and Au JL (2003) Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 63:579-585.
34. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
35. Multani AS, Li C, Ozen M, Imam AS, Wallace S, and Pathak S (1999) Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. Oncol Rep 6:39-44.
36. Olaussen KA, Dubrana K, Domont J, Spano JP, Sabatier L, and Soria JC (2006) Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hematol 57:191-214.
37. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696-1708.
38. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520.
39. Phatak P, Dai F, Butler M, Nandakumar MP, Gutierrez PL, Edelman MJ, Hendriks H, and Burger AM (2008) KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res 14:4593-4602.
40. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, et al. (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757.
41. Reya T, Morrison SJ, Clarke MF, and Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
42. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, et al. (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15:735-741.
43. Smith V, Dai F, Spitz M, Peters GJ, Fiebig HH, Hussain A, and Burger AM (2009) Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents. J Chemother 21:542-549.
44. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, et al. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860.
45. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348.
46. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, et al. (2010) Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28:649-660.
47. Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, and Hussain A (2006) Docetaxel followed by castration improves outcomes in LNCaP prostate cancerbearing severe combined immunodeficient mice. Clin Cancer Res 12:169-174.
48. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512.
49. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972.
50. Visvader JE and Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768.
51. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, and Kyprianou N (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992-8002.